Marc Bourliere, MD, PhD

Hopital Saint Joseph
Marseille, Provence-Alpes-Cote d'Azur, France

Disclosure(s): AbbVie: Board Member, Expert Testimony; Gilead Sciences, Inc.: Board Member, Expert Testimony; Intercept: Board Member, Expert Testimony; Roche: Board Member, Expert Testimony

Presentation(s):

• 83 - Predictors of Undetectable HDV RNA 48 weeks after completion of finite treatment with Bulevirtide and Pegylated-Interferon Alpha 2a

  Thursday, October 17, 2024
  10:45 AM – 11:00 AM US PT